All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-04-10T10:56:12.000Z

Visual abstract | Key updates to the classification of MDS in the 5th WHO Classification of Haematolymphoid Tumours

By Dylan Barrett
Apr 10, 2023
Share:
Learning objective: After reading this article, learners will be able to recall key changes to the classification of myelodysplastic syndromes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours.

Bookmark this article

The AML Hub is pleased to present a visual abstract summarizing the key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Updates include the grouping of myelodysplastic syndromes (MDS) entities as genetically or morphologically defined and the addition of MDS-SF3B1, MDS-5q, and MDS-biTP53 as genetically defined subtypes. Terminology describing the types of childhood MDS have been revised and the diagnostic criteria for chronic myelomonocytic leukemia have been amended.


 

Visual Abstract

To download this visual abstract, click below.

Download here

More about...
Diagnostic and treatment guidelinesDiseaseMDSVisual abstracts

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 80 days left ...

Related articles

Add bookmark

Initiation of the phase I/II ReSET-02 trial of SMART101 for the treatment of AML

On September 27, 2023, it was announced that the first two patients had received SMART101 in the multicenter, open-lab, dose-escalation, phase I/II ReSET-02 trial.

Sep 28, 2023
Add bookmark

Initiation of the phase I/II ReSET-02 trial of SMART101 for the treatment of AML

On September 27, 2023, it was announced that the first two patients had received SMART101 in the multicenter, open-lab,...

Sep 28, 2023
Add bookmark

Visual abstract | Phase I/II trial of SAR443579 in patients with R/R AML, B-ALL, or HR-MDS

The AML Hub is pleased to present a visual abstract summarizing the preliminary safety and efficacy results from the phase I/II trial investigating SAR’579, a...

Jul 26, 2023
Add bookmark

Visual abstract | Phase I/II trial of SAR443579 in patients with R/R AML, B-ALL, or HR-MDS

The AML Hub is pleased to present a visual abstract summarizing the preliminary safety and efficacy results...

Jul 26, 2023
Add bookmark

Visual abstract | Phase III trial of gilteritinib maintenance therapy in patients with mutated FLT3-ITD AML (MORPHO)

The AML Hub is pleased to present a visual abstract summarizing the key results from the phase III MORPHO trial evaluating...

Jul 20, 2023
Add bookmark

Visual abstract | Phase III trial of gilteritinib maintenance therapy in patients with mutated FLT3-ITD AML (MORPHO)

The AML Hub is pleased to present a visual abstract summarizing the key results...

Jul 20, 2023
Add bookmark

Real-world validation of the IPSS-M risk stratification model for MDS and comparison to IPSS-R

The MDS Hub summarizes several presentations from ASH 2022 discussing the implementation of IPSS-M and comparing the prognostic ability of this model with...

Feb 2, 2023
Add bookmark

Real-world validation of the IPSS-M risk stratification model for MDS and comparison to IPSS-R

The MDS Hub summarizes several presentations from ASH 2022 discussing the implementation of IPSS-M and...

Feb 2, 2023

Newsletter

Subscribe to get the best content related to AML delivered to your inbox